Maintenance Notice

Due to necessary scheduled maintenance, the JMIR Publications website will be unavailable from Wednesday, July 01, 2020 at 8:00 PM to 10:00 PM EST. We apologize in advance for any inconvenience this may cause you.

Who will be affected?

Currently submitted to: JMIR Dermatology

Date Submitted: Sep 21, 2026
Open Peer Review Period: Oct 1, 2026 - Nov 26, 2026
(currently open for review)

Warning: This is an author submission that is not peer-reviewed or edited. Preprints - unless they show as "accepted" - should not be relied on to guide clinical practice or health-related behavior and should not be reported in news media as established information.

Giant Cellulitis-like Sweet Syndrome Mimicking Necrotizing Fasciitis in a Patient with Underlying B-Cell Lymphoproliferative Disorder

  • Haddaya Umar; 
  • David Melanson Jr; 
  • Carly Achterberg; 
  • Areeba Minhaj; 
  • Hammad Chaudhry; 
  • Dawlat Khan

ABSTRACT

Introduction: Giant cellulitis-like Sweet syndrome (GCLSS) is a rare variant of Sweet syndrome (acute febrile neutrophilic dermatosis) characterized by painful erythematous plaques that can mimic severe bacterial skin and soft tissues infections like cellulitis and necrotizing fasciitis. Recognition of the condition is challenging as the patient develops rapidly progressive erythema, pain, leukocytosis, and skin necrosis, prompting equally rapid treatment despite being an inflammatory process instead of an infectious one. Case Presentation: A 76-year-old woman with a history of heart failure, Type 2 diabetes mellitus, B-cell lymphoproliferative disorder, and morbid obesity, presented with an extensive, poorly demarcated erythematous rash across her gluteal region and rapidly progressing to involve the bilateral posterolateral thighs. The patient was originally treated for bilateral cellulitis with broad-spectrum; however, the eruption continued to progress with increasing pain, violaceous purpura, bullae, skin induration and areas of necrosis. Necrotizing fasciitis became the primary concern and resulted in surgical exploration which demonstrated viable tissue without fascial necrosis or the typical dishwater fluid. Blood and tissue cultures remained negative while a skin biopsy taken during the surgery demonstrated papillary edema and mixed dermal inflammation with neutrophils without definitive vasculitis or necrosis. Given the bilateral distribution, lack of response to antibiotics, negative cultures, elevated inflammatory markers, leukocytosis, and histopathologic findings, GCLSS was considered in the setting of an underlying malignancy. Antibiotics were then discontinued and intravenous methylprednisolone was initiated, resulting in marked improvement in pain and erythema within 48 hours, thus confirming the diagnosis of GCLSSS. The patient was subsequently transitioned to oral prednisone with a planned taper and outpatient oncological follow-up. Conclusion: GCLSS should be considered in patients with obesity and an underlying malignancy presenting with rapidly progressive rash mimicking cellulitis or necrotizing fasciitis, particularly when lesions are bilateral, cultures remain negative, and there is inadequate response to antibiotic therapies. Recognition of this condition is important to prevent unnecessary surgical intervention and delay of corticosteroid therapy.


 Citation

Please cite as:

Umar H, Melanson D Jr, Achterberg C, Minhaj A, Chaudhry H, Khan D

Giant Cellulitis-like Sweet Syndrome Mimicking Necrotizing Fasciitis in a Patient with Underlying B-Cell Lymphoproliferative Disorder

JMIR Preprints. 21/09/2026:112639

DOI: 10.2196/preprints.112639

URL: https://preprints.jmir.org/preprint/112639

Download PDF


Request queued. Please wait while the file is being generated. It may take some time.

© The authors. All rights reserved. This is a privileged document currently under peer-review/community review (or an accepted/rejected manuscript). Authors have provided JMIR Publications with an exclusive license to publish this preprint on it's website for review and ahead-of-print citation purposes only. While the final peer-reviewed paper may be licensed under a cc-by license on publication, at this stage authors and publisher expressively prohibit redistribution of this draft paper other than for review purposes.